Talha Badar, Hematology/Oncology Specialist at Mayo Clinic shared a post on X:
“All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia | New England Journal of Medicine
An all-oral option for older/unfit newly diagnosed AML. In ASCERTAIN-V, oral decitabine-cedazuridine and venetoclax achieved CR 47%, CR/CRi 63%, mOS 15.5 mo, with no DDI.
Single-arm data; marrow-guided dose/schedule changes to mitigate cytopenias remain essential.”
Title: All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Authors: Gail J. Roboz, Amer M. Zeidan, Gabriel N. Mannis, Pau Montesinos, Montserrat Arnan, Michael R. Savona, Olatoyosi Odenike, James K. McCloskey, Harshad V. Amin, Amir T. Fathi, Teresa Bernal del Castillo, Gabriela Rodríguez-Macías, Jane L. Liesveld, Annie P. Im, Jan Cerny, Teresa C. Gentile, Aram Oganesian, Danna Chan, Yubing Wan, Margit Dijkstra, Harold N. Keer, Elizabeth A. Griffiths, Courtney D. DiNardo
Other articles featuring Talha Badar on OncoDaily.
